JPH0832633B2 - ワクチン - Google Patents

ワクチン

Info

Publication number
JPH0832633B2
JPH0832633B2 JP62062352A JP6235287A JPH0832633B2 JP H0832633 B2 JPH0832633 B2 JP H0832633B2 JP 62062352 A JP62062352 A JP 62062352A JP 6235287 A JP6235287 A JP 6235287A JP H0832633 B2 JPH0832633 B2 JP H0832633B2
Authority
JP
Japan
Prior art keywords
vaccine
host
interferon
adjuvant
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62062352A
Other languages
English (en)
Japanese (ja)
Other versions
JPS62277328A (ja
Inventor
ヒュー リョン プレイフェアー ジョン
Original Assignee
ベ−リンガ− インゲルハイム インタ−ナシヨナル ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868606559A external-priority patent/GB8606559D0/en
Priority claimed from GB868606560A external-priority patent/GB8606560D0/en
Application filed by ベ−リンガ− インゲルハイム インタ−ナシヨナル ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク filed Critical ベ−リンガ− インゲルハイム インタ−ナシヨナル ゲゼルシヤフト ミツト ベシユレンクテル ハフツンク
Publication of JPS62277328A publication Critical patent/JPS62277328A/ja
Publication of JPH0832633B2 publication Critical patent/JPH0832633B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP62062352A 1986-03-17 1987-03-17 ワクチン Expired - Lifetime JPH0832633B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868606559A GB8606559D0 (en) 1986-03-17 1986-03-17 Vaccines
GB8606560 1986-03-17
GB8606559 1986-03-17
GB868606560A GB8606560D0 (en) 1986-03-17 1986-03-17 Vaccines

Publications (2)

Publication Number Publication Date
JPS62277328A JPS62277328A (ja) 1987-12-02
JPH0832633B2 true JPH0832633B2 (ja) 1996-03-29

Family

ID=26290503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62062352A Expired - Lifetime JPH0832633B2 (ja) 1986-03-17 1987-03-17 ワクチン

Country Status (13)

Country Link
EP (1) EP0241725B1 (2)
JP (1) JPH0832633B2 (2)
AU (1) AU607130B2 (2)
CA (1) CA1323302C (2)
DE (1) DE3782960T2 (2)
DK (1) DK175283B1 (2)
ES (1) ES2052503T3 (2)
FI (1) FI93423C (2)
GR (1) GR3007080T3 (2)
IE (1) IE59927B1 (2)
IL (1) IL81920A (2)
NO (1) NO871071L (2)
NZ (1) NZ219631A (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
DE69104619T2 (de) * 1990-08-31 1995-04-13 Schering Corp Verwendungsmethoden von humanem Gammainterferon 4-134.
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
AU2003268688A1 (en) * 2002-09-30 2004-04-19 Yamanouchi Pharmaceutical Co., Ltd. Method of inducing immune responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
US4938956A (en) * 1987-04-01 1990-07-03 International Minerals & Chemical Corp. Synergistic immunostimulating composition and method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｅｕｒ．Ｊ．ＣｌｉｎＭｉｃｒｏｂｉｏｌ，Ｖｏｌ．３Ｎｏ．３（１９８４），ＰＰ．１９５−１９８
Ｎａｔｕｒｅ，Ｖｏｌ．２９４（１９８１），ＰＰ．３６１−３６４

Also Published As

Publication number Publication date
JPS62277328A (ja) 1987-12-02
DK133287A (da) 1987-09-18
DE3782960T2 (de) 1993-04-29
FI871131L (fi) 1987-09-18
AU607130B2 (en) 1991-02-28
NO871071D0 (no) 1987-03-16
EP0241725A3 (en) 1989-05-10
CA1323302C (en) 1993-10-19
FI93423B (fi) 1994-12-30
DK175283B1 (da) 2004-08-09
FI871131A0 (fi) 1987-03-16
IL81920A (en) 1991-12-12
NZ219631A (en) 1990-03-27
AU7008687A (en) 1987-09-24
DE3782960D1 (de) 1993-01-21
GR3007080T3 (2) 1993-07-30
IE59927B1 (en) 1994-05-04
FI93423C (fi) 1995-04-10
EP0241725A2 (en) 1987-10-21
ES2052503T3 (es) 1994-07-16
NO871071L (no) 1987-09-18
IE870684L (en) 1987-09-17
EP0241725B1 (en) 1992-12-09
DK133287D0 (da) 1987-03-16
IL81920A0 (en) 1987-10-20

Similar Documents

Publication Publication Date Title
JP4126067B2 (ja) アジュバント組成物
Heppner et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes
US9732122B2 (en) Attenuated recombinant vesicular stomatitis viruses comprising modified matrix proteins
Golovliov et al. Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis
WO1994001133A1 (en) Use of gm-csf as a vaccine adjuvant
KR20000029747A (ko) 말라리아에대한백신조성물
JPS63500591A (ja) プラスモディウム　ビバックス　スポロゾイド外被タンパク質に相当する免疫原性ペプチド抗原
Hoffman et al. Progress toward malaria preerythrocytic vaccines
JPH0832633B2 (ja) ワクチン
Sällberg et al. A malaria vaccine candidate based on a hepatitis B virus core platform
Zhang et al. Protective immunity induced by 67 K outer membrane protein of phase I Coxiella burnetii in mice and guinea pigs
Croft et al. TraT: a powerful carrier molecule for the stimulation of immune responses to protein and peptide antigens
US20060073171A1 (en) Vaccine composition against malaria
EA006211B1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
Davis DNA-based immunization against hepatitis B: experience with animal models
CN100333791C (zh) 抗疟疾的疫苗接种方法
KR100905249B1 (ko) Ｄｎａ와 항원의 조합에 의해 효능이 증강된 백신포뮬레이션
Hilleman Immunologic prevention of human hepatitis
Heppner et al. Adjuvanted RTS, S and other protein-based pre-erythrocytic stage malaria vaccines
Riddell et al. Tropical disease vaccines
Ballou et al. The development of molecular vaccines against malaria sporozoites
US20040156866A1 (en) Vaccine to protect animals against leishmania
Kang The 19-kDa carboxyl-terminal region of merozoite surface protein-1 as a vaccine candidate against malaria
JP2003277292A (ja) マラリア原虫伝搬阻止粘膜ワクチン
Chai The humoral response to a chemically defined synthetic vaccine comprised of epitopes derived from the circumsporozoite protein of Plasmodium berghei

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term